Vincerx Pharma, Inc. Unit
VINCU
VINCU was delisted on the 25th of March, 2021.
6 hedge funds and large institutions have $38.7M invested in Vincerx Pharma, Inc. Unit in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$9.63M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.63M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$8.19M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$7.7M |
| 5 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$540K |
Top Sellers
VINCU Hedge Fund Activity: Q4 2020 in Review
6 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Unit (VINCU) for Q4 2020, worth a combined $38.7M.
Buyers outnumbered sellers: 6 funds opened new VINCU positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Putnam Investments, opening a new position worth an estimated $9.63M.
- 6 institutional investors held Vincerx Pharma, Inc. Unit (VINCU) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $38.7M of Vincerx Pharma, Inc. Unit stock for Q4 2020.
- 6 funds opened new Vincerx Pharma, Inc. Unit positions in Q4 2020 and 0 closed out, a net change of +6 holders.
- The largest Vincerx Pharma, Inc. Unit buyer in Q4 2020 was Putnam Investments, an estimated $9.63M added.
Based on aggregated 13F filings for Q4 2020.